We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Procedureless Gastric Balloon Encourages Weight Loss

By HospiMedica International staff writers
Posted on 23 Dec 2015
An innovative gastric balloon offers an alternative treatment option for overweight and obese individuals. More...


The Elipse procedureless gastric balloon is a thin, flexible polymer film balloon that is delivered in a swallowable capsule, thus eliminating the need for surgery, endoscopy, or anesthesia. Once in position, it is filled with liquid through a thin delivery catheter, which is then detached by tugging. The gastric balloon remains in the stomach for four months, after which it automatically empties and is excreted naturally from the body. The Elipse will be offered by physicians in conjunction with a medically supervised diet and exercise program.

The Elipse has undergone clinical studies in people with a body mass index (BMI) of 27-40 kg/m2. Study findings indicated an average weight loss of 10 kilograms, with participants losing 37% of their excess weight and eight centimeters off their waist circumference over the four month treatment period. Participants also saw improvements in triglyceride and hemoglobin HbA1c levels, and all balloons were safely and naturally excreted. The Elipse procedureless gastric balloon is a product of Allurion Technologies (Wellesley, MA, USA), and has received the European Community CE marking of approval.

“Excess weight often has a profound impact on health and quality of life, including work, relationships, and self-perception. But of nearly two billion overweight and obese adults worldwide, less than one percent have embraced currently available surgical and endoscopic options,” said Shantanu Gaur, MD, co-founder and chief scientific officer of Allurion Technologies. “Weight loss therapies that require surgery, endoscopy, or anesthesia are often too invasive and can be too expensive for people who might otherwise greatly benefit from them.”

“Following six years of development, we are very excited to enter the next phase of our company's growth,” said Jonathan Wecker, CEO of Allurion Technologies. “I am extremely proud of our team and thankful for the support of the many physicians and allied caregivers that have helped make Elipse a reality.”

Related Links:

Allurion Technologies



Gold Member
12-Channel ECG
CM1200B
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Wound Irrigation Solution
Prontosan®
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Masimo smartSET pulse oximetry with PPG AFib and OIRD Detection (Photo courtesy of Masimo)

Smart Pulse Oximetry Supports Earlier Recognition of Arrhythmias and Respiratory Risk

On general care floors, respiratory compromise and arrhythmias can develop between routine checks. Atrial fibrillation often goes undiagnosed in older adults, while opioid-induced respiratory depression... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Brain PET imaging could help identify Alzheimer’s patients most likely to benefit from available therapies (Image Credit: iStock)

Amyloid and Tau PET Guide Selection and Monitoring of Alzheimer’s Therapy

Alzheimer’s disease is the most common form of dementia and can be difficult to distinguish from other causes of cognitive decline. According to the World Health Organization (WHO), 57 million people were... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.